Literature DB >> 16928853

Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia.

Agnes Nadjar1, Jonathan M Brotchie, Celine Guigoni, Qin Li, Shao-Bo Zhou, Gui-Jie Wang, Paula Ravenscroft, François Georges, Alan R Crossman, Erwan Bezard.   

Abstract

The classic view of anatomofunctional organization of the basal ganglia is that striatopallidal neurons of the "indirect" pathway express D2 dopamine receptors and corelease enkephalin with GABA, whereas striatopallidal neurons of the "direct" pathway bear D1 dopamine receptors and corelease dynorphin and substance P with GABA. Although many studies have investigated the pathophysiology of the basal ganglia after dopamine denervation and subsequent chronic levodopa (L-dopa) treatment, none has ever considered the possibility of plastic changes leading to profound reorganization and/or biochemical phenotype modifications of medium spiny neurons. Therefore, we studied the phenotype of striatal neurons in four groups of nonhuman primates, including the following: normal, parkinsonian, parkinsonian chronically treated with L-dopa without exhibiting dyskinesia, and parkinsonian chronically treated with L-dopa exhibiting overt dyskinesia. To identify striatal cells projecting to external (indirect) or internal (direct) segments of the globus pallidus, the retrograde tracer cholera toxin subunit B (CTb) was injected stereotaxically into the terminal areas. Using immunohistochemistry techniques, brain sections were double labeled for CTb and dopamine receptors, opioid peptides, or the substance P receptor (NK1). We also used HPLC-RIA to assess opioid levels throughout structures of the basal ganglia. Our results suggest that medium spiny neurons retain their phenotype because no variations were observed in any experimental condition. Therefore, it appears unlikely that dyskinesia is related to a phenotype modification of the striatal neurons. However, this study supports the concept of axonal collateralization of striatofugal cells that project to both globus pallidus pars externa and globus pallidus pars interna. Striatofugal pathways are not as segregated in the primate as previously considered.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16928853      PMCID: PMC6674386          DOI: 10.1523/JNEUROSCI.2582-06.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  63 in total

1.  Ultrastructural immunocytochemical localization of the dopamine D2 receptor and tyrosine hydroxylase in the rat ventral pallidum.

Authors:  Elisa Mengual; Virginia M Pickel
Journal:  Synapse       Date:  2002-03-01       Impact factor: 2.562

2.  Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons.

Authors:  O Aizman; H Brismar; P Uhlén; E Zettergren; A I Levey; H Forssberg; P Greengard; A Aperia
Journal:  Nat Neurosci       Date:  2000-03       Impact factor: 24.884

3.  Phenotypical characterization of the neurons expressing the D1 and D2 dopamine receptors in the monkey striatum.

Authors:  I Aubert; I Ghorayeb; E Normand; B Bloch
Journal:  J Comp Neurol       Date:  2000-02-28       Impact factor: 3.215

4.  Dopamine D2 receptors are present in prefrontal cortical afferents and their targets in patches of the rat caudate-putamen nucleus.

Authors:  Hong Wang; Virginia M Pickel
Journal:  J Comp Neurol       Date:  2002-01-21       Impact factor: 3.215

5.  Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter.

Authors:  M Jaber; B Dumartin; C Sagné; J W Haycock; C Roubert; B Giros; B Bloch; M G Caron
Journal:  Eur J Neurosci       Date:  1999-10       Impact factor: 3.386

6.  Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

Authors:  E Bezard; S Dovero; C Prunier; P Ravenscroft; S Chalon; D Guilloteau; A R Crossman; B Bioulac; J M Brotchie; C E Gross
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

7.  Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.

Authors:  B C Tel; B-Y Zeng; C Cannizzaro; R K B Pearce; S Rose; P Jenner
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

8.  Detection of human T-lymphotropic virus type I p40tax protein in cerebrospinal fluid cells from patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Authors:  T Moritoyo; S Izumo; H Moritoyo; Y Tanaka; Y Kiyomatsu; M Nagai; K Usuku; M Sorimachi; M Osame
Journal:  J Neurovirol       Date:  1999-06       Impact factor: 2.643

9.  Activation of ventral tegmental area cells by the bed nucleus of the stria terminalis: a novel excitatory amino acid input to midbrain dopamine neurons.

Authors:  François Georges; Gary Aston-Jones
Journal:  J Neurosci       Date:  2002-06-15       Impact factor: 6.167

10.  Neuroendocrine differentiation in gastric adenocarcinomas associated with severe hypergastrinemia and/or pernicious anemia.

Authors:  Gunnar Qvigstad; Tor Qvigstad; Bjørn Westre; Arne K Sandvik; Eiliv Brenna; Helge L Waldum
Journal:  APMIS       Date:  2002-02       Impact factor: 3.205

View more
  31 in total

Review 1.  The external globus pallidus: progress and perspectives.

Authors:  Daniel J Hegeman; Ellie S Hong; Vivian M Hernández; C Savio Chan
Journal:  Eur J Neurosci       Date:  2016-03-28       Impact factor: 3.386

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

3.  Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.

Authors:  Yunmin Ding; Jacqueline Restrepo; Lisa Won; Dong-Youn Hwang; Kwang-Soo Kim; Un Jung Kang
Journal:  Neurobiol Dis       Date:  2007-04-10       Impact factor: 5.996

4.  A biologically constrained model of the whole basal ganglia addressing the paradoxes of connections and selection.

Authors:  Jean Liénard; Benoît Girard
Journal:  J Comput Neurosci       Date:  2014-06       Impact factor: 1.621

5.  The endocannabinoid 2-arachidonoylglycerol mediates D1 and D2 receptor cooperative enhancement of rat nucleus accumbens core neuron firing.

Authors:  T Seif; A Makriyannis; G Kunos; A Bonci; F W Hopf
Journal:  Neuroscience       Date:  2011-07-27       Impact factor: 3.590

Review 6.  Human and rodent homologies in action control: corticostriatal determinants of goal-directed and habitual action.

Authors:  Bernard W Balleine; John P O'Doherty
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

7.  Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells.

Authors:  Orhan Tansel Korkmaz; Neşe Tunçel; Muzaffer Tunçel; Elif Mine Oncü; Varol Sahintürk; Mustafa Celik
Journal:  J Mol Neurosci       Date:  2009-12-02       Impact factor: 3.444

8.  Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia.

Authors:  Emanuela Santini; Veronique Sgambato-Faure; Qin Li; Marc Savasta; Sandra Dovero; Gilberto Fisone; Erwan Bezard
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

9.  Basal Ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia.

Authors:  Pedro Barroso-Chinea; Erwan Bezard
Journal:  Front Neuroanat       Date:  2010-09-14       Impact factor: 3.856

10.  Dissociable effects of dopamine on neuronal firing rate and synchrony in the dorsal striatum.

Authors:  John M Burkhardt; Xin Jin; Rui M Costa
Journal:  Front Integr Neurosci       Date:  2009-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.